drugset / Trial / NCT04573218

Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia

NCT04573218 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

An unpublished study by the investigators on healthy participants has shown that the supplementation of oil palm phenolics (OPP) at 250 mg is the optimum dose to demonstrate the ability to lower total and LDL cholesterol. There is no clinical evidence as yet on that optimum dosage of OPP supplementation in improving fasting lipid profile in minor hyperlipidemia subjects. The investigators hypothesize that in a clinical study, OPP supplemented to the minor hyperlipidemic participants will elicit a reduction in total and LDL cholesterol while maintaining safety and tolerability. OPP may have the potential to be positioned as natural health supplement in improving lipid profile.

Timeline

Start
2021-10-18
Primary completion
2021-12-16
Completion
2021-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Oil Palm Phenolics Unknown 250 mg Oral

Indications